WO2016077565A3 - Methods for chronic pain management and treatment using hcg - Google Patents

Methods for chronic pain management and treatment using hcg Download PDF

Info

Publication number
WO2016077565A3
WO2016077565A3 PCT/US2015/060348 US2015060348W WO2016077565A3 WO 2016077565 A3 WO2016077565 A3 WO 2016077565A3 US 2015060348 W US2015060348 W US 2015060348W WO 2016077565 A3 WO2016077565 A3 WO 2016077565A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcg
day
chronic pain
treatment
methods
Prior art date
Application number
PCT/US2015/060348
Other languages
French (fr)
Other versions
WO2016077565A2 (en
Inventor
Jr. Edson Conrad Hicks
Constance T. Dutton
Original Assignee
Neuralight Hd, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/539,940 external-priority patent/US20150290293A1/en
Application filed by Neuralight Hd, Llc filed Critical Neuralight Hd, Llc
Priority to EP15859240.2A priority Critical patent/EP3217999A4/en
Priority to CN201580073070.2A priority patent/CN107206057A/en
Publication of WO2016077565A2 publication Critical patent/WO2016077565A2/en
Publication of WO2016077565A3 publication Critical patent/WO2016077565A3/en
Priority to IL252239A priority patent/IL252239B/en
Priority to HK18103822.8A priority patent/HK1244231A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A61M5/284—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A61M5/31545—Setting modes for dosing
    • A61M5/31548—Mechanically operated dose setting member
    • A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M2005/1401—Functional features
    • A61M2005/1405—Patient controlled analgesia [PCA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A gonadotropin is administered within a surprisingly effective narrow range for the purpose of treating chronic pain or other central sensitization sequelae. In one aspect, a recipient is provided with at least one of human chorionic gonadotropin (uHCG and /or rHCG), a pharmaceutically active HCG analogue, and a pharmaceutically active metabolite of the HCG or analogue at a dosage selected to provide an amount therapeutically bioequivalent to, a human subcutaneous dosage of between 120 IU/day and 170 IU/day of HCG, and more preferably between 140 IU/day and 160 IU/day of HCG. A combination product is also described, which includes a supply of the HCG-related drug, a delivery device, and a conversion scale for therapeutic bioequivalence that identifies the specific amount and route of administration for chronic pain or central sensitization as an indication of the drug.
PCT/US2015/060348 2014-11-12 2015-11-12 Methods for chronic pain management and treatment using hcg WO2016077565A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP15859240.2A EP3217999A4 (en) 2014-11-12 2015-11-12 Methods for chronic pain management and treatment using hcg
CN201580073070.2A CN107206057A (en) 2014-11-12 2015-11-12 The method for being handled with HCG and treating chronic ache
IL252239A IL252239B (en) 2014-11-12 2017-05-11 Human chorionic gonadotropin for use in treating a central sensitization disorder
HK18103822.8A HK1244231A1 (en) 2014-11-12 2018-03-19 Methods for chronic pain management and treatment using hcg

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/539,940 US20150290293A1 (en) 2011-04-15 2014-11-12 Methods for chronic pain management and treatment using hcg
US14/539,940 2014-11-12

Publications (2)

Publication Number Publication Date
WO2016077565A2 WO2016077565A2 (en) 2016-05-19
WO2016077565A3 true WO2016077565A3 (en) 2016-06-30

Family

ID=55955258

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/060348 WO2016077565A2 (en) 2014-11-12 2015-11-12 Methods for chronic pain management and treatment using hcg

Country Status (5)

Country Link
EP (1) EP3217999A4 (en)
CN (1) CN107206057A (en)
HK (1) HK1244231A1 (en)
IL (1) IL252239B (en)
WO (1) WO2016077565A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190071490A1 (en) 2017-03-02 2019-03-07 Beth Israel Deaconess Medical Center, Inc. Preventing Post-Ictal Headaches

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032954A1 (en) * 2002-10-11 2004-04-22 Milkhaus Laboratory, Inc. Method of treating chronic pelvic pain syndrome by administration of chrorionic gonadotropin
WO2004069271A1 (en) * 2003-02-07 2004-08-19 Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Use of human chorionic gonadotropin in the treatment in the treatment of symptoms caused by endometriosis
US8680088B2 (en) * 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130157939A1 (en) * 2010-08-23 2013-06-20 Shmuel Ben-Sasson Compositions for gastric delivery of active agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032954A1 (en) * 2002-10-11 2004-04-22 Milkhaus Laboratory, Inc. Method of treating chronic pelvic pain syndrome by administration of chrorionic gonadotropin
WO2004069271A1 (en) * 2003-02-07 2004-08-19 Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Use of human chorionic gonadotropin in the treatment in the treatment of symptoms caused by endometriosis
US8680088B2 (en) * 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOREST TENNANT: "The Use of Hormones for Chronic Pain", JOURNAL OF PROLOTHERAPY, vol. 2, no. 4, 2010, pages 489 - 495, XP055142166 *

Also Published As

Publication number Publication date
WO2016077565A2 (en) 2016-05-19
IL252239B (en) 2022-02-01
IL252239A0 (en) 2017-07-31
HK1244231A1 (en) 2018-08-03
CN107206057A (en) 2017-09-26
EP3217999A2 (en) 2017-09-20
EP3217999A4 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
MX2021004546A (en) Implantable drug delivery compositions and methods of use thereof.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
JP2013155188A5 (en)
MX2016011333A (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine.
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
MY196869A (en) Cancer treatment combinations
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
JP2016532516A5 (en)
MX2019011620A (en) Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors.
MX359672B (en) Methods for chronic pain management and treatment using hcg.
CO6771406A2 (en) A combined composition
EA201391689A1 (en) SYSTEM OF DELIVERY MEDICINE
MX2021004883A (en) Methods and compositions for treating sleep apnea.
MX2015009546A (en) Increased dosage of efavirenz for the treatment of cancer.
WO2016077565A3 (en) Methods for chronic pain management and treatment using hcg
EA201591603A1 (en) NEW THERAPEUTIC COMBINATIONS MYRTAZAPINE FOR APPLICATION IN PAIN DISEASES
PH12017500617A1 (en) Dosage regimen for pegylated interferon
TW201642854A (en) Fixed dose combination for pain relief without edema
MX2018005298A (en) Dosage regimen for a phosphatidylinositol 3-kinase inhibitor.
MX2018005876A (en) Plasminogen dosage regimen for wound healing.
MX2018011293A (en) Prolonged release pharmaceutical composition comprising cysteamine or salt thereof.
JOP20170044B1 (en) Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
AR104177A1 (en) SYSTEM FOR THE ADMINISTRATION OF DRUGS IN THE LAGRIMAL GLAND
MY174442A (en) Treating critically ill patients with intravenous ibuprofen
PH12018500889A1 (en) Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 252239

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015859240

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15859240

Country of ref document: EP

Kind code of ref document: A2